These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25224346)

  • 21. High frequency of highly active antiretroviral therapy modifications in patients with acute or early human immunodeficiency virus infection.
    Sabundayo BP; McArthur JH; Langan SJ; Gallant JE; Margolick JB
    Pharmacotherapy; 2006 May; 26(5):674-81. PubMed ID: 16637796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of the magnitude and associated factors of immunological failure among adult and adolescent HIV-infected patients in St. Luke and Tulubolo Hospital, Oromia Region, Ethiopia.
    Bayou B; Sisay A; Kumie A
    Pan Afr Med J; 2015; 21():291. PubMed ID: 26587140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Highly active antiretroviral therapy (HAART) in HIV-positive pregnant women in the Netherlands, 1997-2003: safe, effective and with few side effects].
    Tempelman C; Timmermans S; Godfried MH; Dieleman JP; Boer K; van der Ende ME
    Ned Tijdschr Geneeskd; 2004 Oct; 148(41):2021-5. PubMed ID: 15553999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of highly active antiretroviral therapy in HIV-1 infected children.
    van Rossum AM; Fraaij PL; de Groot R
    Lancet Infect Dis; 2002 Feb; 2(2):93-102. PubMed ID: 11901656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    Siegfried N; van der Merwe L; Brocklehurst P; Sint TT
    Cochrane Database Syst Rev; 2011 Jul; (7):CD003510. PubMed ID: 21735394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective observation for seven-year's highly active antiretroviral therapy in Chinese HIV-1 infected patients.
    He M; Zheng YH; Zhou HY; Mamadou D; Chen Z; Chen X; Yao YH; He Y
    Curr HIV Res; 2011 Apr; 9(3):160-5. PubMed ID: 21585332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia.
    Birlie B; Braekers R; Awoke T; Kasim A; Shkedy Z
    BMC Infect Dis; 2017 Jun; 17(1):453. PubMed ID: 28655306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection.
    Mocroft A; Phillips AN; Soriano V; Rockstroh J; Blaxhult A; Katlama C; Boron-Kaczmarska A; Viksna L; Kirk O; Lundgren JD;
    AIDS Res Hum Retroviruses; 2005 Sep; 21(9):743-52. PubMed ID: 16218797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
    Lowe SH; Wensing AM; Hassink EA; ten Kate RW; Richter C; Schreij G; Koopmans PP; Juttmann JR; van der Tweel I; Lange JM; Borleffs JC
    HIV Clin Trials; 2005; 6(5):235-45. PubMed ID: 16306030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiretroviral changes during the first year of therapy.
    Bandeira ACPCS; Elias DBD; Cavalcante MG; Lima DGL; Távora LGF
    Rev Assoc Med Bras (1992); 2017 Jul; 63(7):606-612. PubMed ID: 28977086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adherence to Antiretroviral Therapy Among Iranian HIV/AIDS Patients.
    Khalili H; Rohani R; Seyedalinaghi S; Hajiabdolbaghi M; Dashti-Khavidaki S; Talasaz AH
    Curr Clin Pharmacol; 2012 May; 7(2):111-115. PubMed ID: 22432842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study).
    Burger DM; Aarnoutse RE; Dieleman JP; Gyssens IC; Nouwen J; de Marie S; Koopmans PP; Stek M; van der Ende ME
    Antivir Ther; 2003 Oct; 8(5):455-61. PubMed ID: 14640393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical trial comparing efficacy and safety of four highly active antiretroviral therapy (HAART) in antiretroviral-naive treatment with advanced HIV infection].
    Geijo Martínez MP; Maciá Martínez MA; Solera Santos J; Barberá Farré JR; Rodríguez Zapata M; Marcos Sánchez F; Martínez Alfaro E; Cuadra García-Tenorio F; Sanz Moreno J; Moreno Mendaña JM; Beato Pérez JL; Sanz Sanz J;
    Rev Clin Esp; 2006 Feb; 206(2):67-76. PubMed ID: 16527165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The influence of patient beliefs and treatment satisfaction on the discontinuation of current first-line antiretroviral regimens.
    Casado JL; Marín A; Romero V; Bañón S; Moreno A; Perez-Elías MJ; Moreno S; Rodriguez-Sagrado MA
    HIV Med; 2016 Jan; 17(1):46-55. PubMed ID: 26149493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A prospective study of adverse events to antiretroviral therapy in HIV- infected adults in Ekiti State, Nigeria.
    Popoola TD; Awodele O; Oshikoya KA
    Afr J Med Med Sci; 2016 Jun; 45(2):179-187. PubMed ID: 29465861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Initial therapy of HIV infection.
    Gallant JE
    J Clin Virol; 2002 Dec; 25(3):317-33. PubMed ID: 12423696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV infection and advanced age emerging epidemiological, clinical, and management issues.
    Manfredi R
    Ageing Res Rev; 2004 Jan; 3(1):31-54. PubMed ID: 15164725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.
    Ruof J; Dusek A; DeSpirito M; Demasi RA
    Clin Drug Investig; 2007; 27(7):469-79. PubMed ID: 17563127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.
    de la Rosa R; Ruíz-Mateos E; Rubio A; Abad MA; Vallejo A; Rivero L; Genebat M; Sánchez-Quijano A; Lissen E; Leal M
    J Antimicrob Chemother; 2004 Jan; 53(1):95-101. PubMed ID: 14657091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.